Author

M. Diamond

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 7 Immunology· 4 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 11 Research Focus:host-pathogen & immune response· 10 Organism:human· 6 Organism:mouse· 6 Assay:proteomics· 5 Research Focus:drug response / drug discovery· 3 Assay:bulk RNA-seq· 2 Approach:deep learning· 2

Frequent Co-Authors

J. E. Crowe· 5 shared J. B. Case· 4 shared A. Boon· 3 shared P. Gilchuk· 3 shared A. Bailey· 2 shared A. Hassan· 2 shared A. Joshi· 2 shared B. Whitener· 2 shared

Activity by Year

2020-2023 · peak 6/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

J. E. Crowe

Mutual co-authors in cluster

Author profile →

12 papers

Recent·Most cited

Sequential early-life viral infections modulate the microbiota and adaptive immune responses to systemic and mucosal vaccination

Y. Li, J. M. Molleston, A. H. Kim, H. Ingle, S. Aggarwal, L. Nolan, A. Hassan, L. Foster, M. Diamond, M. T. Baldridge

This study shows that sequential early-life viral infections in mice reduce antibody responses to SARS-CoV-2 vaccination while altering immune cell profiles and gut microbiota.

bioRxiv · Aug 31, 2023Microbiology

NVX-CoV2373 ancestral and NVX-CoV2540 BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters

T. L. Bricker, A. Joshi, N. Soudani, S. Scheaffer, N. Patel, M. G. Xabier, G. Smith, M. Diamond, A. C. Boon

This study evaluates the efficacy of NVX-CoV2373 and NVX-CoV2540 nanoparticle vaccines against the Omicron BA.5 variant in Syrian hamsters, showing reduced viral infection and better protection compared to mRNA vaccines.

bioRxiv · Aug 7, 2023Microbiology

Potent and pan-neutralization of SARS-CoV-2 variants of concern by DARPins

V. K. Chonira, Y.-D. Kwon, J. Gorman, J. B. Case, Z. Ku, R. Simeon, R. G. Casner, D. R. Harris, A. S. Olia, T. Stevens, L. Shapiro, H. Boyd, Y. Tsybovsky, F. Krammer, M. Diamond, , Z. Chen

This paper reports the development of two DARPins, FSR16m and FSR22, that potently neutralize SARS-CoV-2 variants, including emerging ones, with efficacy comparable to therapeutic antibodies.

bioRxiv · May 30, 2022 · PreprintBioengineering

Isolation of a potently neutralizing and protective human monoclonal antibody targeting yellow fever virus

J. E. Crowe, M. Doyle, J. R. Genualdi, A. Bailey, N. Kose, C. Gainza, J. Rodriguez, K. M. Reeder, C. A. Nelson, P. N. Jethva, R. E. Sutton, R. G. Bombardi, M. Gross, J. G. Julander, D. H. Fremont, M. Diamond

The paper isolates a human monoclonal antibody that neutralizes yellow fever virus and provides therapeutic protection in animal models.

bioRxiv · Feb 28, 2022Immunology

mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2

T. L. Darling, B. Ying, B. Whitener, L. VanBlargan, T. L. Bricker, C.-Y. Liang, A. Joshi, G. Bamunuarachchi, K. Seehra, A. Schmitz, P. Halfmann, Y. Kawaoka, S. Elbashir, D. K. Edwards, L. Thackray, , A. Boon

This study evaluates the efficacy of mRNA-1273 and Ad26.COV2.S vaccines against the B.1.621 variant in mice and hamsters, showing protection against infection and pathology.

bioRxiv · Dec 29, 2021Microbiology

Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617

L. Peng, Y. Hu, M. Mankowski, P. Ren, R. Chen, J. Wei, M. Zhao, T. Li, T. Tripler, L. Ye, R. Chow, Z. Fang, C. Wu, M. Dong, M. Cook, , S. Chen

The paper develops and characterizes monospecific and bispecific monoclonal antibodies that neutralize SARS-CoV-2 and its variants, including B.1.617.2 Delta.

bioRxiv · Dec 21, 2021Immunology

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies

L. A. VanBlargan, J. M. Errico, P. Halfmann, S. J. Zost, J. E. Crowe, L. A. Purcell, Y. Kawaoka, D. Corti, D. H. Fremont, M. Diamond

This study evaluates the neutralization of the SARS-CoV-2 Omicron variant by therapeutic monoclonal antibodies and finds that several lose efficacy against the variant.

bioRxiv · Dec 15, 2021Microbiology

Mesalamine Reduces Intestinal ACE2 Expression Without Modifying SARS-CoV-2 Infection or Disease Severity in Mice.

D. M. Alvarado, J. Son, L. B. Thackray, M. Diamond, S. Ding, M. A. Ciorba, Washington University IBD Investigators Group

This study investigates whether mesalamine affects SARS-CoV-2 infection and disease severity in mice and human intestinal cells, finding no change in viral levels but reduced ACE2 expression.

bioRxiv · Jul 23, 2021Microbiology

A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope

L. VanBlargan, L. Adams, Z. Liu, R. E. Chen, P. Gilchuk, S. Raju, B. Smith, H. Zhao, J. B. Case, E. S. Winkler, B. Whitener, L. Droit, I. Aziati, P.-Y. Shi, A. Creanga, , M. Diamond

The paper identifies an antibody that neutralizes all SARS-CoV-2 variants by targeting a conserved epitope on the spike protein.

bioRxiv · Apr 26, 2021Microbiology

Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail

J. Dong, S. Zost, A. Greaney, T. N. Starr, A. S. Dingens, E. C. Chen, R. Chen, B. Case, R. Sutton, P. Gilchuk, J. Rodriguez, E. Armstrong, C. Gainza, R. Nargi, E. Binshtein, , J. E. Crowe

This paper determines the structures of two antibodies in the AZD7442 cocktail that neutralize SARS-CoV-2 and identifies critical residues for neutralization and viral escape.

bioRxiv · Jan 27, 2021 · PreprintImmunology

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection

E. S. Winkler, P. Gilchuk, J. Yu, A. L. Bailey, R. E. Chen, S. J. Zost, H. Jang, Y. Huang, J. D. Allen, J. B. Case, R. E. Sutton, R. H. Carnahan, T. L. Darling, A. C. M. Boon, M. Mack, , M. Diamond

This study shows that neutralizing antibodies against SARS-CoV-2 need intact Fc functions and monocytes for optimal therapeutic protection in animal models.

bioRxiv · Dec 28, 2020Immunology

A single intranasal or intramuscular immunization with chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters.

T. Bricker, T. Darling, A. Hassan, H. Harastani, A. Soung, X. Jiang, Y.-N. Dai, H. Zhao, L. Adams, M. Holtzman, A. Bailey, J. B. Case, D. Fremont, R. S. Klein, M. Diamond, A. Boon

This study compares intranasal and intramuscular delivery of a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine in hamsters, finding that intranasal immunization provides superior protection against infection and inflammation.

bioRxiv · Dec 2, 2020Microbiology